Home › Companies › Northwest Biotherapeutics, Inc. › 2025-2026
At Northwest Biotherapeutics, Inc.'s shareholder meeting held December 29, 2025, in the 2025-2026 proxy season, 72 asset managers reported how they voted in their SEC Form N-PX filings, covering 82 separate fund positions. Their filings are grouped here into 4 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the Company's executive compensation; — FOR was 77% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Northwest Biotherapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on January 2, 2026.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Northwest Biotherapeutics, Inc.’s Form 8-K, filed January 2, 2026 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of December 29, 2025: 4 items on Northwest Biotherapeutics, Inc.’s Form 8-K, filed January 2, 2026: 4 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2023-2024 2025-2026
Explore Northwest Biotherapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Northwest Biotherapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed January 2, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| 1. Election of Directors. The common and preferred stockholders, voting as a single class, approved the election of Mr. Pat Sarma for a new three-year term as Class II member of the Board of Directors. Mr. Pat Sarma | 739,207,750 | 0 | -- | 172,286,240 | 280,993,355 | 81% | Not verified | — |
| 2. Ratification of Appointment of Registered Public Accounting Firm. The common and preferred stockholders, voting as a single class, ratified the appointment of Cherry Bekaert LLP as the Company's independent registered public accounting firm for the fiscal y | 1,143,100,380 | 38,271,749 | 11,115,216 | -- | 0 | 97% | Not verified | — |
| 3. Approval of Common Stock Increase Amendment. The common and preferred stockholders, voting together as a single class, approved the Common Stock Increase Amendment to increase the number of authorized shares of Common Stock | 1,056,740,073 | 122,050,303 | 13,696,969 | -- | 280,993,355 | 90% | Not verified | — |
| 4. Advisory Vote on Executive Compensation. The common and preferred stockholders, voting as a single class, approved the Company's executive compensation. approval | 667,767,433 | 196,915,765 | 46,810,792 | -- | 280,993,355 | 77% | Not verified | — |
Source: Northwest Biotherapeutics, Inc., Form 8-K, filed with the SEC on January 2, 2026 — read the filing on EDGAR.
Each item below shows how the 72 asset managers that disclosed a Northwest Biotherapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Northwest Biotherapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 2 wordings of this item as funds reported it.
100% of fund votes cast · no official result
The 2 asset managers below reported 71,000 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Roberts Wealth Advisors, LLC | 65,000 | 0 | 0 | 0 | For |
| Berkeley Capital Partners, LLC | 6,000 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
90% Majority: yes · of votes cast
Description as filed by funds: To approve an amendment to our Amended and Restated Certificate of Incorporation, as amended (the "Certificate of Incorporation"), to increase our authorized shares of common stock from 1,700,000,000 to 2,600,000,000, par value $0.001 per share (the "Common Stock").
Northwest Biotherapeutics, Inc.’s own tally for this item (“3. Approval of Common Stock Increase Amendment. The common and preferred stockholders, voting together as a single class, approved the Common Stock Increase Amendment to increase the number of authorized shares of Common”): 1,056,740,073 for, 122,050,303 against, per its Form 8-K filed January 2, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 2 asset managers below reported 71,000 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Roberts Wealth Advisors, LLC | 65,000 | 0 | 0 | 0 | For |
| Berkeley Capital Partners, LLC | 6,000 | 0 | 0 | 0 | For |
Combines 6 wordings of this item as funds reported it.
77% Majority: yes · of votes cast
Description as filed by funds: To approve, on an advisory basis, the Company's executive compensation;
Northwest Biotherapeutics, Inc.’s own tally for this item (“4. Advisory Vote on Executive Compensation. The common and preferred stockholders, voting as a single class, approved the Company's executive compensation. approval”): 667,767,433 for, 196,915,765 against, per its Form 8-K filed January 2, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 77% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 72 asset managers below reported 11,081,267 for, 30,725 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BNY Mellon | 4,774,973 | 0 | 0 | 0 | For |
| MidFirst Bank | 1,674,501 | 0 | 0 | 0 | For |
| HighTower Advisors, LLC | 1,145,165 | 0 | 0 | 0 | For |
| Badgley Phelps Wealth Managers, LLC | 614,820 | 0 | 0 | 0 | For |
| SPIREPOINT PRIVATE CLIENT, LLC | 340,000 | 0 | 0 | 0 | For |
| Corient Private Wealth LP | 339,203 | 0 | 0 | 0 | For |
| CIBC Private Wealth Group LLC | 297,259 | 0 | 0 | 0 | For |
| Fisher Asset Management, LLC | 292,498 | 0 | 0 | 0 | For |
| Cerity Partners LLC | 251,150 | 0 | 0 | 0 | For |
| OPPENHEIMER & CO INC | 247,280 | 0 | 0 | 0 | For |
| JOHNSON INVESTMENT COUNSEL INC | 149,940 | 0 | 0 | 0 | For |
| SIGMA INVESTMENT COUNSELORS INC | 130,215 | 0 | 0 | 0 | For |
| WELLS FARGO CLEARING SERVICES, LLC | 126,413 | 0 | 0 | 0 | For |
| MERCER GLOBAL ADVISORS INC /ADV | 99,646 | 0 | 0 | 0 | For |
| Roberts Wealth Advisors, LLC | 65,000 | 0 | 0 | 0 | For |
| PNC BANK, NATIONAL ASSOCIATION | 50,000 | 0 | 0 | 0 | For |
| Ashurst Perkins Coie Trust Co | 47,500 | 0 | 0 | 0 | For |
| CHEVY CHASE TRUST Co | 37,854 | 0 | 0 | 0 | For |
| TRUIST FINANCIAL CORP | 33,485 | 0 | 0 | 0 | For |
| CHOREO, LLC | 25,000 | 0 | 0 | 0 | For |
| Capita Financial Network | 23,000 | 0 | 0 | 0 | For |
| MONETA GROUP INVESTMENT ADVISORS LLC | 20,500 | 0 | 0 | 0 | For |
| Cresset Asset Management, LLC | 20,000 | 0 | 0 | 0 | For |
| SCOTIA CAPITAL INC. | 20,000 | 0 | 0 | 0 | For |
| Azimuth Capital Investment Management LLC | 19,700 | 0 | 0 | 0 | For |
Showing the 25 largest of 72 asset managers. All 72 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Description as filed by funds: To ratify the appointment of Cherry Bekaert LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.
Northwest Biotherapeutics, Inc.’s own tally for this item (“2. Ratification of Appointment of Registered Public Accounting Firm. The common and preferred stockholders, voting as a single class, ratified the appointment of Cherry Bekaert LLP as the Company's independent registered”): 1,143,100,380 for, 38,271,749 against, per its Form 8-K filed January 2, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 2 asset managers below reported 71,000 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Roberts Wealth Advisors, LLC | 65,000 | 0 | 0 | 0 | For |
| Berkeley Capital Partners, LLC | 6,000 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 1,540,682,082 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BNY Mellon | 0.31% |
| 2 | MidFirst Bank | 0.11% |
| 3 | HighTower Advisors, LLC | 0.07% |
| 4 | Badgley Phelps Wealth Managers, LLC | 0.04% |
| 5 | SPIREPOINT PRIVATE CLIENT, LLC | 0.02% |
| 6 | Corient Private Wealth LP | 0.02% |
| 7 | CIBC Private Wealth Group LLC | 0.02% |
| 8 | Fisher Asset Management, LLC | 0.02% |
| 9 | Cerity Partners LLC | 0.02% |
| 10 | OPPENHEIMER & CO INC | 0.02% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Linda F. Powers | 1.91% | DEF14A |
| Pat Sarma | 0.48% | DEF14A |
| Marnix L. Bosch, Ph.D., M.B.A. | <0.01% | DEF14A |
| Alton L. Boynton, Ph.D | <0.01% | DEF14A |
| Dr. Navid Malik | <0.01% | DEF14A |
Percentages above are of 1,540,682,082 shares outstanding, as reported by Northwest Biotherapeutics, Inc. on its Form 10-Q dated November 13, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Northwest Biotherapeutics, Inc.’s 10-Q dated November 13, 2025. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
Northwest Biotherapeutics, Inc. proxy season coverage: 2023-2024 · 2025-2026 (this page).
proxyvotesnow.com, “Northwest Biotherapeutics (NWBO) 2025 Annual Meeting (2025-2026 season)”, https://proxyvotesnow.com/company/northwest-biotherapeutics-inc/2026 (version of November 9, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.